Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of “Buy” from Brokerages

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) has received a consensus rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $11.71.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Rani Therapeutics in a report on Tuesday, November 19th.

Insider Activity at Rani Therapeutics

In related news, insider Kate Mckinley acquired 17,960 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was acquired at an average price of $1.67 per share, with a total value of $29,993.20. Following the purchase, the insider now directly owns 17,960 shares in the company, valued at approximately $29,993.20. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 53.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Stifel Financial Corp boosted its holdings in shares of Rani Therapeutics by 100.4% during the 3rd quarter. Stifel Financial Corp now owns 269,768 shares of the company’s stock valued at $583,000 after acquiring an additional 135,148 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Rani Therapeutics by 14.3% during the third quarter. Geode Capital Management LLC now owns 172,261 shares of the company’s stock valued at $372,000 after purchasing an additional 21,527 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Rani Therapeutics during the second quarter valued at about $81,000. King Luther Capital Management Corp increased its stake in shares of Rani Therapeutics by 44.5% in the third quarter. King Luther Capital Management Corp now owns 81,129 shares of the company’s stock valued at $175,000 after buying an additional 25,000 shares during the period. Finally, Janney Montgomery Scott LLC bought a new position in Rani Therapeutics in the 4th quarter valued at approximately $37,000. 30.19% of the stock is currently owned by institutional investors and hedge funds.

Rani Therapeutics Stock Down 0.8 %

RANI stock opened at $1.31 on Tuesday. The company has a market cap of $75.05 million, a PE ratio of -1.24 and a beta of 0.16. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 2.34. Rani Therapeutics has a 52 week low of $1.24 and a 52 week high of $8.75. The business has a 50-day simple moving average of $1.70 and a 200 day simple moving average of $2.34.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.